CHRO
Price:
$1.35
Market Cap:
$8.90M
Channel Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.
Industry
Biotechnology
IPO Date
2024-02-16
Stock Exchange
AMEX
Ticker
CHRO
According to Channel Therapeutics Corporation’s latest financial reports and current stock price. The company's current ROE is 345.57%. This represents a change of 14.50% compared to the average of 301.81% of the last 4 quarters.
The mean historical ROE of Channel Therapeutics Corporation over the last ten years is 101.72%. The current 345.57% ROE has changed 239.72% with respect to the historical average. Over the past ten years (40 quarters), CHRO's ROE was at its highest in in the June 2024 quarter at 970.64%. The ROE was at its lowest in in the March 2024 quarter at -226.73%.
Average
101.72%
Median
66.33%
Minimum
16.18%
Maximum
293.12%
Discovering the peaks and valleys of Channel Therapeutics Corporation ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 310.01%
Maximum Annual ROE = 293.12%
Minimum Annual Increase = -12.38%
Minimum Annual ROE = 16.18%
Year | ROE | Change |
---|---|---|
2024 | 293.12% | 155.94% |
2023 | 114.53% | 72.66% |
2022 | 66.33% | 310.01% |
2021 | 16.18% | -12.38% |
The current ROE of Channel Therapeutics Corporation (CHRO) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
157.99%
5-year avg
101.72%
10-year avg
101.72%
Channel Therapeutics Corporation’s ROE is
Company | ROE | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Channel Therapeutics Corporation using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Channel Therapeutics Corporation or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Channel Therapeutics Corporation's ROE?
How is the ROE calculated for Channel Therapeutics Corporation (CHRO)?
What is the highest ROE for Channel Therapeutics Corporation (CHRO)?
What is the 3-year average ROE for Channel Therapeutics Corporation (CHRO)?
What is the 5-year average ROE for Channel Therapeutics Corporation (CHRO)?
How does the current ROE for Channel Therapeutics Corporation (CHRO) compare to its historical average?